All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
acr_session2.jpeg

EULAR 2021 – Day 2 Report

Jack Cush, MD

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
lung%2Cbright.jpg

New insights in RA-ILD therapeutics

Aurelie Najm, MD, PhD

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis.
But why would we want to diagnose early a manifestation that we cannot treat?

Read Article
Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
Janet Pope Janetbirdope ( View Tweet)
#Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting for comorbidities- so many diagnoses with RA ⬇️outcomes only defined as >1 drug #EULAR2021 @RheumNow OP0098 https://t.co/lMazBDTPw1
Janet Pope Janetbirdope ( View Tweet)
A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay #EULAR2021 Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006. https://t.co/6GhSLXqysd https://t.co/h2k00GzHE5

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% with advanced Rx were difficult to treat vs 39% if > 1 ts\bDMARDs. Worse pts had ⬆️disease duration. Drug resistance over time? POS0405 @RheumNow #EULAR2021 @eular_org

Janet Pope Janetbirdope ( View Tweet)

Stop #smoking! Smoking is not good for you & others! 👉🏽Passive smoking exposures during childhood & adulthood associated with increased risk of #RheumatoidArthritis Could favour citrullination in genetically proned people By @YannNgyn OP0012 #EULAR2021 #rheumatoid https://t.co/ImDR0aLAXd
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)

JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr

Janet Pope Janetbirdope ( View Tweet)
JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 ⁦@RheumNow⁩ https://t.co/XV7wVJsE9c
Janet Pope Janetbirdope ( View Tweet)
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/PJODe0U6wr

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6
Richard Conway RichardPAConway ( View Tweet)
Pregnancy is a minefield for RA pts: dx activity➡️preg risk PNL➡️preg risk, but dx activity proxy? bring on Swedish/Danish linked data: 1739 RA preg matched 1:10 ⬆️pre-term/SGA risk with bDMARDs/PNL adj for dx activity: less bad, but still concern? OP0210 #EULAR2021 @RheumNow https://t.co/AlwFtmGcZH
David Liew drdavidliew ( View Tweet)
In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities! #EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP
Aurelie Najm AurelieRheumo ( View Tweet)
Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1000 pyrs. After 5yrs RTX show > risk of ACS compared to ETA. In patient with >= 2 previous DMARDs ABA, INF and RTX > risk of ACS compared to ETA. #EULAR2021 @Rheumnow #OP0114 https://t.co/MjW9LI2cjt
Aurelie Najm AurelieRheumo ( View Tweet)
Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest? #EULAR2021 @Rheumnow #OP0116

Aurelie Najm AurelieRheumo ( View Tweet)

Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up. Tight and early disease control reduces CV burden! #EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
Aurelie Najm AurelieRheumo ( View Tweet)
In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts. #EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
Aurelie Najm AurelieRheumo ( View Tweet)
MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN in RA patients with sustained SDAI remission receiving combination ETN+MTX. ETA > MTX for maintaining SDAI remission at W48 (49.5%-28.7% P=0.004) #EULAR2021 @Rheumnow #OP0118 https://t.co/MSOclXGMEK
Aurelie Najm AurelieRheumo ( View Tweet)
Can we predict pre-clinical RA-ILD? @Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%) #POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×